非小细胞肺癌千表皮生长因子受体酪氨酸激酶抑制剂（英文）.pptVIP

YMC Epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer Yuh-Min Chen, MD, PhD. Chest Dept., Taipei VGH Activation of the epidermal growth factor receptor tyrosine kinase (EGFR-TK): a pivotal driver of carcinogenesis IDEAL 1 and 2 trial design IDEAL 1 and 2: overall survival by symptom improvement (250 mg/day) ISEL (IRESSA Survival Evaluation in Lung Cancer): Clinical Trial Design ISEL - Overall Survival ISEL Survival: Orientals RESULTS 3 CR, 9 PR, with a R.R. of 33.3% SD 14, control rate of 72.2% All treatment-related toxicities were few and mild in sever